While the sequencing of the human genome made it possible for researchers to analyze the expression of a myriad of disease-related genes at high-throughput, these efforts fail to capture the important features of the many diseases which result from abnormal protein expression, post-translational modification, or interaction with other biomolecules. Thus, genomics approaches alone cannot provide a complete understanding of the molecular basis of disease. Ultimately, efficient, high-throughput protein analysis is also required for building a complete picture of disease states and developing the prognostics, diagnostics, and therapeutics needed to ensure health.

In 2001, RayBiotech addressed this need by introducing the first commercially available cytokine antibody array. Since then, we’ve continued to innovate around both multiplex and individual protein detection and quantification, creating products that deliver accurate, precise, and sensitive measurements while also conserving limited samples.

We’ve expanded these innovations to include hundreds of arrays, immunoassays, and related reagents for efficient analysis of proteins involved in inflammation, angiogenesis, apoptosis, cell growth, and signal transduction.

We also enable scientists to efficiently and confidently discover more through a comprehensive suite of services, which leverage the scientific expertise used to develop our innovative platforms to advance scientific projects outside of RayBiotech.